Cuba has approved the extensive use of Citoprot-P and DPT-HB-HIB vaccine, both developed by its Center of Genetic Engineering and Biotechnology.
The latter is fit to fight diphtheria, whooping cough, tetanus, hepatitis B and haemophilus influenzae type B, is the second of its type in the world and first produced by a developing country.
CIGB director Dr. Luis Herrera added that the vaccine will simplify and reduce immunization programs for the Cuban population.
Citoprot-P is considered a unique choice for diabetic patients to prevent amputation caused by aggressive injuries, added the specialist.
Both medications underwent tight screening and efficiency tests before they were approved by the State Medical Quality Control Center.
Herrera explained that after earning a domestic license Cuba arranged for international registration and sales license.
Since its July 1, 1986 inauguration, the CIGB has registered 28 quality products, the best known its recombinant vaccine for hepatitis B, the recombinant streptoquinase for cardiac arrests, interferon and skin growth factor.